TY - JOUR
T1 - Society of pediatric liver transplantation
T2 - Current registry status 2011-2018
AU - the Society of Pediatric Liver Transplantation Research Group
AU - Elisofon, Scott A.
AU - Magee, John C.
AU - Ng, Vicky L.
AU - Horslen, Simon P.
AU - Fioravanti, Vicki
AU - Economides, Julie
AU - Erinjeri, Jinson
AU - Anand, Ravinder
AU - Mazariegos, George V.
AU - Dunn, S.
AU - Martin, A.
AU - Mannino, D.
AU - Flynn, L.
AU - Mohammad, S.
AU - Alonso, E.
AU - Superina, R.
AU - Brandt, K.
AU - Riordan, M.
AU - Lokar, J.
AU - Ito, J.
AU - Elisofon, S.
AU - Zapata, L.
AU - Jain, A.
AU - Foristal, E.
AU - Gupta, N.
AU - Whitlow, C.
AU - Naik, K.
AU - Espinosa, H.
AU - Miethke, A.
AU - Hawkins, A.
AU - Hardy, J.
AU - Engels, E.
AU - Schreibeis, A.
AU - Ovchinsky, N.
AU - Kogan-Liberman, D.
AU - Cunningham, R.
AU - Malik, P.
AU - Sundaram, S.
AU - Feldman, A.
AU - Garcia, B.
AU - Yanni, G.
AU - Kohli, R.
AU - Emamaullee, J.
AU - Secules, C.
AU - Magee, J.
AU - Lopez, J.
AU - Bilhartz, J.
AU - Hollenbeck, J.
AU - Mavis, A.
AU - Nadig, S.
N1 - Publisher Copyright:
© 2019 Wiley Periodicals, Inc
PY - 2020/2/1
Y1 - 2020/2/1
N2 - Background: SPLIT was founded in 1995 in order to collect comprehensive prospective data on pediatric liver transplantation, including waiting list data, transplant, and early and late outcomes. Since 2011, data collection of the current registry has been refined to focus on prospective data and outcomes only after transplant to serve as a foundation for the future development of targeted clinical studies. Objective: To report the outcomes of the SPLIT registry from 2011 to 2018. Methods: This is a multicenter, cross-sectional analysis characterizing patients transplanted and enrolled in the SPLIT registry between 2011 and 2018. All patients, <18 years of age, received a first liver-only, a combined liver-kidney, or a combined liver-pancreas transplant during this study period. Results: A total of 1911 recipients from 39 participating centers in North America were registered. Indications included biliary atresia (38.5%), metabolic disease (19.1%), tumors (11.7%), and fulminant liver failure (11.5%). Greater than 50% of recipients were transplanted as either Status 1A/1B or with a MELD/PELD exception score. Incompatible transplants were performed in 4.1%. Kaplan-Meier estimates of 1-year patient and graft survival were 97.3% and 96.6%. First 30 days of surgical complications included reoperation (31.7%), hepatic artery thrombosis (6.3%), and portal vein thrombosis (3.2%). In the first 90 days, biliary tract complications were reported in 13.6%. Acute cellular rejection during first year was 34.7%. At 1 and 2 years of follow-up, 39.2% and 50.6% had normal liver tests on monotherapy (tacrolimus or sirolimus). Further surgical, survival, allograft function, and complications are detailed.
AB - Background: SPLIT was founded in 1995 in order to collect comprehensive prospective data on pediatric liver transplantation, including waiting list data, transplant, and early and late outcomes. Since 2011, data collection of the current registry has been refined to focus on prospective data and outcomes only after transplant to serve as a foundation for the future development of targeted clinical studies. Objective: To report the outcomes of the SPLIT registry from 2011 to 2018. Methods: This is a multicenter, cross-sectional analysis characterizing patients transplanted and enrolled in the SPLIT registry between 2011 and 2018. All patients, <18 years of age, received a first liver-only, a combined liver-kidney, or a combined liver-pancreas transplant during this study period. Results: A total of 1911 recipients from 39 participating centers in North America were registered. Indications included biliary atresia (38.5%), metabolic disease (19.1%), tumors (11.7%), and fulminant liver failure (11.5%). Greater than 50% of recipients were transplanted as either Status 1A/1B or with a MELD/PELD exception score. Incompatible transplants were performed in 4.1%. Kaplan-Meier estimates of 1-year patient and graft survival were 97.3% and 96.6%. First 30 days of surgical complications included reoperation (31.7%), hepatic artery thrombosis (6.3%), and portal vein thrombosis (3.2%). In the first 90 days, biliary tract complications were reported in 13.6%. Acute cellular rejection during first year was 34.7%. At 1 and 2 years of follow-up, 39.2% and 50.6% had normal liver tests on monotherapy (tacrolimus or sirolimus). Further surgical, survival, allograft function, and complications are detailed.
KW - liver transplantation
KW - outcomes
KW - pediatrics
UR - http://www.scopus.com/inward/record.url?scp=85074750458&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85074750458&partnerID=8YFLogxK
U2 - 10.1111/petr.13605
DO - 10.1111/petr.13605
M3 - Article
C2 - 31680409
AN - SCOPUS:85074750458
SN - 1397-3142
VL - 24
JO - Pediatric transplantation
JF - Pediatric transplantation
IS - 1
M1 - e13605
ER -